MIST News and Press, Milestone Pharmaceuticals Inc.

MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced details on RESET-PSVT, a planned Phase 4, mul...

MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the  25 ...

MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express Scripts, one of the n...

2026-03-20 18:32:16 ET Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call March 20, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

2026-03-20 08:05:18 ET More on Milestone Pharmaceuticals Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense Seeking Alpha’s Quant Rating on Milestone Pharmaceutical...

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo CARDAMYST ...

Creative Medical Technology Holdings Inc. (CELZ) is expected to report $-0.37 for Q4 2025 Creative Realities Inc. (CREX) is expected to report $-0.07 for Q4 2025 BitFuFu Inc. (FUFU) is expected to report $-0.01 for Q4 2025 Moleculin Biotech Inc. (MBRX) is expected to report $-7.76 for...

MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled ...

2026-03-14 02:49:46 ET Overview My last analysis of Milestone Pharmaceuticals ( MIST ) immediately followed the FDA approval of CARDAMYST (etripamil), a calcium channel blocker administered intranasally to terminate PSVT in adults. I spent a lot of time talking about the alt...

MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement wil...